AXSM 250516 105.00P(AXSM250516P105000) Stock Price Today

US OptionsDetailed Quotes

AXSM250516P105000

Watchlist

2.05
-0.35-14.58%

15min DelayClose Apr 30 16:00 ET

2.28High2.05Low

Intraday

5D
Daily

News

RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $193
Moomoo NewsApr 30 03:33 ET · Ratings
Earnings Preview: AXSM to Report Financial Results Pre-market on May 05
Moomoo NewsApr 29 21:00 ET
Axsome Therapeutics Price Target Raised to $193.00/Share From $190.00 by RBC Capital
Dow JonesApr 29 13:08 ET · Ratings
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Dow JonesApr 29 13:08 ET · Ratings
Axsome Therapeutics Analyst Ratings
BenzingaApr 29 12:54 ET · Ratings
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)
TipRanksApr 29 06:50 ET · Ratings

Comments

Teddy123

Apr 1 19:05

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

$Axsome Therapeutics (AXSM.US)$
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup

Teddy123

Mar 5 21:04

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

$Axsome Therapeutics (AXSM.US)$
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement

Teddy123

Mar 3 20:09

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

$Axsome Therapeutics (AXSM.US)$
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Teddy123

Feb 24 20:18

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

$Axsome Therapeutics (AXSM.US)$
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate

Teddy123

Feb 18 20:17

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$Axsome Therapeutics (AXSM.US)$
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate